Navigation Links
New study finds that PROMETAT, a controversial methamphetamine treatment program, is ineffective
Date:11/14/2011

A recent study has found that PROMETAT, a popular but controversial treatment for methamphetamine addiction, is no more effective than placebo in reducing methamphetamine use, keeping users in treatment, or reducing cravings for methamphetamine. The study was funded by Hythiam, the company that owns the PROMETAT protocol, and is published online today in the scientific journal Addiction.

Methamphetamine, also known as meth, crystal meth, or ice, is the second most abused illicit drug in the world (cannabis is first), with 15-16 million regular users. The United States saw a rapid growth in methamphetamine addiction in the early 2000s. It was during that epidemic that PROMETAT burst onto the public scene through an aggressive marketing campaign.

Since its introduction, the PROMETAT protocol has been widely used in specialized private clinics in the U.S. as a treatment for methamphetamine addiction without going through the normal drug approval process. Normally, introducing a new medication requires approval by the U.S. Food and Drug Administration, including tests of product safety and a clinical trial to make sure the treatment produces the predicted effects. A loophole in this regulatory system allows a combination of previously approved medications to be marketed without review, whether or not the individual medications were originally approved as a treatment for the condition the new protocol targets. The manufacturer of PROMETAT, Hythiam, was therefore able to market and sell the new protocol with no federal review or clinical trial evidence.

Private patients reportedly pay $12,000 to $15,000 for one month of treatment.

Hythiam used some of its profits to fund the clinical trials long called for by the scientific community, including this one, designed and led by Dr. Walter Ling, a respected U.S. scientist and expert on methamphetamine addiction. Ling and his fellow researchers found that the group of participants given the PROMETAT treatment did not have better outcomes than those given placebo in terms of reducing methamphetamine use, retention in treatment, or reducing methamphetamine cravings.


'/>"/>

Contact: Jean O'Reilly
jean@addictionjournal.org
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Drinking Risky for Women With Family History of Breast Cancer: Study
2. Mayo Clinic study confirms smoke-free workplaces reduce heart attacks
3. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
4. Sugar-Sweetened Drinks May Pose Heart Risks to Women, Study Suggests
5. Stem cell study helps clarify the best time for therapy to aid heart attack survivors
6. Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure
7. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
8. Study Suggests Exercise May Help Memory of Fibromyalgia Patients
9. Regular Teeth Cleanings Could Cut Heart Attack Risk: Study
10. Abused Girls at Greater Risk for Heart Disease as Adults: Study
11. Intensive Control of Type 1 Diabetes Helps Kidneys: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/20/2017)... ... 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built ... is mounted on wheels, it can be wheeled out of the way and stored when ... the deck. "We have transformed the feedback from customers into specific enhancements and created a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology: